Novartis Ag Adr (NVS)

Apr 30, 2026

Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.

Apr 30, 2026

Apr 30, 2026

Novartis AG Stock (CH0012005267): Q1 Revenue Miss Triggers Decline - AD HOC NEWS

Apr 30, 2026

Apr 30, 2026

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility - ChartMill

Apr 30, 2026

Apr 29, 2026

Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates - Sahm

Apr 29, 2026

Apr 28, 2026

Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips - Investing.com

Apr 28, 2026

Apr 28, 2026

Earnings call transcript: Novartis Q1 2026 earnings miss forecasts, stock dips By Investing.com - Investing.com Canada

Apr 28, 2026

Apr 28, 2026

Novartis (NYSE: NVS) Q1 2026 earnings dip as key drugs surge, Avidity deal closes - Stock Titan

Apr 28, 2026

Apr 28, 2026

NVS Technical Analysis | Trend, Signals & Chart Patterns | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill

Apr 28, 2026

Apr 28, 2026

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed - ChartMill

Apr 28, 2026

Apr 27, 2026

NVS Stock Price, Quote & Chart | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill

Apr 27, 2026

Apr 27, 2026

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria - ChartMill

Apr 27, 2026

Apr 24, 2026

Novartis AG (NVS) Stock Price, Trades & News - GuruFocus

Apr 24, 2026

Apr 24, 2026

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA) - ChartMill

Apr 24, 2026

Apr 23, 2026

Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.

Apr 23, 2026

Apr 22, 2026

NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill

Apr 22, 2026

Apr 21, 2026

Peptide Drug Conjugate Market Landscape Report 2026: A $1.5 Billion Opportunity by 2031 - GlobeNewswire Inc.

Apr 21, 2026

Apr 21, 2026

Novartis AG stock (CH0012005267): Is its innovative drug pipeline strong enough to unlock new upside - AD HOC NEWS

Apr 21, 2026

Apr 20, 2026

Novartis AG (MEX:NVSN) Bonds - GuruFocus

Apr 20, 2026

Apr 20, 2026

Novartis AG (MEX:NVSN) Dividend - GuruFocus

Apr 20, 2026

Apr 19, 2026

Novartis AG stock (CH0012005267): Is its focused pharma strategy strong enough to unlock new upside? - AD HOC NEWS

Apr 19, 2026

Apr 18, 2026

Novartis AG (ADR) stock (CH0012005267): Why Google Discover changes matter more now - AD HOC NEWS

Apr 18, 2026

Apr 18, 2026

Novartis AG Stock Baskets | MEX:NVSN - GuruFocus

Apr 18, 2026

Apr 18, 2026

Novartis AG Stock Operating Data - GuruFocus

Apr 18, 2026

Apr 18, 2026

Novartis AG (ADR) stock (CH0012005267): Why its innovative drug pipeline matters more now for invest - AD HOC NEWS

Apr 18, 2026

Apr 18, 2026

Novartis AG (ADR) stock (CH0012005267): Why does its innovative drug pipeline matter more now for in - AD HOC NEWS

Apr 18, 2026

Apr 16, 2026

NVS Stock Quote Price and Forecast - CNN

Apr 16, 2026

Apr 14, 2026

Book value per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets

Apr 14, 2026

Apr 14, 2026

Novartis AG stock (CH0012005267): Is its Innovative Medicines focus strong enough to unlock new upsi - AD HOC NEWS

Apr 14, 2026

Apr 10, 2026

Novartis AG stock: Why Fabhalta momentum matters for investors now - AD HOC NEWS

Apr 10, 2026

Apr 09, 2026

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030 - ChartMill

Apr 09, 2026

Apr 08, 2026

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors - ChartMill

Apr 08, 2026

Apr 08, 2026

Novartis AG stock: What investors should know about its steady pharma powerhouse status - AD HOC NEWS

Apr 08, 2026

Apr 02, 2026

Novartis AG (NVS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 02, 2026

Apr 02, 2026

Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com

Apr 02, 2026

Apr 02, 2026

Novartis AG (ADR) Stock: Resilient Pharma Leader with Strong Fundamentals and Growth Potential for N - AD HOC NEWS

Apr 02, 2026

Apr 02, 2026

Novartis AG Stock: Resilient Pharma Leader with Strong Fundamentals and Strategic Growth Ahead for I - AD HOC NEWS

Apr 02, 2026

Mar 31, 2026

Novartis AG Stock Historical Valuations - GuruFocus

Mar 31, 2026

Mar 27, 2026

Novartis Bolsters Immunology Pipeline With Excellergy Deal - Zacks Investment Research

Mar 27, 2026

Mar 27, 2026

Dow Jones Top Company Headlines at 11 AM ET: Novartis to Buy Excellergy for Up to $2 Billion | Why ... - 富途牛牛

Mar 27, 2026

Mar 27, 2026

Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE therapy - Proactive Investors

Mar 27, 2026

Mar 27, 2026

Novartis AG Stock: Strong Analyst Upgrades and Pipeline Momentum Drive Investor Interest in 2026 - AD HOC NEWS

Mar 27, 2026

Mar 27, 2026

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors - ChartMill

Mar 27, 2026

Mar 26, 2026

Novartis AG (NVS) Bonds - GuruFocus

Mar 26, 2026

Mar 26, 2026

Novartis AG stock gains 2% on SIX Swiss Exchange amid strong SMI performance and positive pharma sec - AD HOC NEWS

Mar 26, 2026